Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | SAGE | Common Stock | Award | $0 | +13.5K | +2571.43% | $0.00 | 14K | Aug 5, 2024 | Direct | F1, F2 |
transaction | SAGE | Common Stock | Tax liability | -$29.5K | -3.29K | -23.44% | $8.96 | 10.7K | Aug 5, 2024 | Direct |
Id | Content |
---|---|
F1 | On February 13, 2024, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 33,750 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on August 5, 2024, resulting in the vesting of the PSUs as to 13,500 shares. |
F2 | Reflects beneficial ownership balance which includes 298 shares purchased on June 28, 2024 under the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan. |